Annual Report: 2020
Dey's Medical Stores (Manufacturing) Ltd. provides standalone financial statements for the period of 01/04/2019 to 31/03/2020. The corporate identity number is U24232WB1957PLC023528. The permanent account number of the entity is AABCD1608D. The address of the registered office is 62 Bondel Road, Kolkata, West Bengal, 700019, India. The type of industry is commercial and industrial. The registration date is 01/08/1957. The company is a Public Company Limited by Shares /Indian Non Government Company. The company is not listed. There are 839 employees at the end of the financial year. The company has not published a sustainability report. The date final accounts were approved was 05/11/2020. The period covered by the financial statements is 12 months, reporting from 01/04/2019 to 31/03/2020. The report is standalone. It contains financial statements, in INR thousands, using thousands level of rounding. The cash flow statement type is indirect method. The registrar and transfer agent is Maheswari Datamatics Pvt. Ltd. located at 23 R N Mukherjee Road, Kolkata 700001. The company does not maintain relevant documents in electronic form. There is one product or service category. The principal product is pharmaceutical products.
The principal products or services are ITONE EYE DROP with a turnover of 2,07,130 and ENTEROMYCETIN SYRUP with a turnover of 1,20,164. The highest turnover for products is ITONE EYE DROP at 2,07,130 and ENTEROMYCETIN SYRUP at 1,20,164.
The unsecured loans are 1,13,062 and total change in indebtness is -1,13,062. The Principal amount at end of financial year is 2,07,70,985 and total indebtedness at end of financial year is 2,07,70,985.
The total number of shares held at end of period for Dey's Medical Stores Pvt Ltd is 8,36,491. The percentage of total shares held at end of period is 98.27%. The total number of shares held at end of period for Gautam Dey is 773. The percentage of total shares held at end of period is 0.09%.
Dey's Medical Stores PVT LTD is a HOLDING company located at 1B, DEODAR STREET, KOLKATA - 700019, INDIA with CIN U51217WB1949PTC017847 and owns 98.27% of shares. The applicable section is 2(46).
Gautam Dey and Ranajit Dey signed the board report on 05/11/2020. Gautam Dey is the Managing Director with DIN 01277238, and Ranajit Dey is the Wholetime Director with DIN 01277323.
There was no change in promoters’ shareholding. The shareholding at the beginning of the year (01/04/2019) was 8,36,491 shares for Dey's Medical Stores PVT LTD and 773 shares for Gautam Dey. The percentage of total shares held was 98.27% and 0.09% respectively. The increase/decrease in shareholding during the year was 0 shares for both, with a 0.00% change. At the end of the period (31/03/2020), the total number of shares held was 8,36,491 and 773 shares, and the percentage of total shares held remained at 98.27% and 0.09%.
The number of demat shares held at the end of period are 0. The number of physical shares held at end of period are 8,51,186. The total number of shares held at end of period are 8,51,186. Percentage of total shares held at end of period are 100.00%. Percentage of change in shares held during year is 0.00%. For Promoters the number of demat shares held at the end of period is 0. The number of physical shares held at end of period are 8,37,264. The total number of shares held at end of period are 8,37,264. Percentage of total shares held at end of period are 98.36%. Percentage of change in shares held during year is 0.00%. Individual / HUF total number of shares held at end of period is 773 and the percentage of total shares held is 0.09%.
The number of demat shares held at end of period are 0. The number of physical shares held end of period are 13,922. The total number of shares held at end of period are 13,922. The percentage of total shares held at end of period is 1.64%. The Percentage of change in shares held during the year is 0.00%. Indian non-corporate bodies physical shares at end of period is 6,091.
New India Assurance Co. Ltd. is the top 1 shareholder, Ruma Rudra is the top 2 shareholder, Nirmal Baran Bhattacharjee is the top 3 shareholder, Sandip Rudra is the top 4 shareholder, Dhruba Das is the top 5 shareholder, Subha Sankar Nandi is the top 6 shareholder, Subrata Basu is the top 7 shareholder, Bani Dey is the top 8 shareholder, Bhupati Mohan Sen is the top 9 shareholder and Prakash Chandra Dey is the top 10 shareholder.
The name of the main product or service is I TONE EYE DROP Enteromycetin Suspension 60 ml and the second product/service is Enteromycetin Suspension 60 ml. The NIC code for I TONE EYE DROP is 30049001 and for Enteromycetin is 30042001. Percentage to total turnover of company for the eye drop is 19.34% and 11.04% for the suspension.
The company's board recommends a transfer of 20000 to General Reserve and recommends payment of dividend @ Re.1 per equity share. The total financial outgo will be Rs. 8.51 lakhs.
Revenue from Operations amounted to Rs.10901.09 Lakhs as compared to Rs.10521.23 Lakhs. Company's Profit before Tax is Rs.942.22 Lakhs against Rs.989.68 Lakhs.
The Company is now fully Schedule M compliant and has now also become GLP (Good Laboratory Practices) compliant.
All operations of the Company were disrupted during the first quarter of the current financial year 2020-21 due to impact of COVID-19.
Sourendro Prasad Saha is due to retire by rotation at the ensuing Annual General Meeting, and is recommended for reappointment.
Rajarshi Dutta was appointed as Chief Executive Officer of the Company from 16th December 2019 till the closing of business hours of 31st December, 2021 on contractual basis.
The Board of Directors duly met five times during the financial year from 1st April, 2019 to 31st March, 2020.
The company has formulated and adopted a Risk Management Policy and taken COVID-19 Insurance Policy upto a sum of Rs.1,00,000/- (Rupees One Lakh) for each employee including contractual employees.
Contracts and Arrangements now existing with Dey's Medical Stores Private Limited (DMSPL) and Dey's Medical (U.P.) Private Limited [DM(UP)PL] were approved by the board as transactions in ordinary course of business on the same footing as if such transactions were entered with unrelated parties on arm's length basis.
Your directors wish to place on record the utmost cooperation and support extended by various departments and agencies of the State & Central Government, UCO Bank, Bandhan Bank, ICICI Bank, Indian Drug Manufacturer's Association (IDMA), Ayurvedic Drug Manufacturer's Association and various Chambers of Commerce, in the various fields of the companies' activities.
M/s. Nundy Roy & Co., Chartered Accountants, was appointed as Auditor of the Company for a period of 5 years.
Details regarding energy conservation are given in Annexure B and Annual Report on CSR Activities is annexed to this Board's Report and marked as Annexure - C. The CSR Policy is available on the website of the Company at the webaddress - www.deysmedical.com
The company implemented conservation of energy which included: continuing upgradation to Heating Ventilation Air-Conditioning and Cooling (HVAC), continuing replacement of old / rewinding motors with energy efficient motors, installation of VFD's in the process equipment's, replacement of partial damaged / old cooling coil of AC pkg unit & Chiller with new one, continuing Cleaning & Maintenance of Boiler with dosing of chemicals in daily / monthly basis, periodic checking of steam lines & its leakage, upgrading and periodic checking of APFC Panels, and contiuning replacement of old 36W/40W tube light fittings with 18W/22W LED fixtures. Improvements include: regularly checking of HVAC systems, replacement of old motors with high energy efficient motors, and the use of VFDs, chemical dosing of chemical and proper cleaning of boiler, and periodic checking of APFC panels. Saving of 10 to 15% of electricity consumption by the implementation of LED fixtures in phase wise.
The Company has developed new processes and has efforts for evaluation of single doses safety and efficacy study of LivinaC/B?B= a polyherbal capsule based on OECD guidelines and Assessment of Acute Oral Toxicity Study of TrasinaC/B?B= - an Ayurvadic Herbal Formulation on Experimental Models.
The expenditure on R & D :Capital Expenditure is 25.53 and Recurring (including Market Research & Development) is 149.32. Total expenses is 174.85. Percentage of Revenue from Operations 1.60
Foreign Exchange Earnings and Outgo. Foreign Exchange Export Sales (FOB) is NIL. Foreign Exchange Outgo (including raw materials, spare parts, Capital Goods and other Expenditure in foreign currency) is 479.79
A brief outline of the Company's CSR Policy include contribution to Prime Minister National Relief Fund, Eradicating extreme hunger and poverty, Promoting education, Promoting Healthcare, Social Business Projects and Ensuring Environmental Sustainability.
Average net profit of the company for last three financial years is Rs.7,37,18,667/- and prescribed CSR Expenditure is Rs.14,74,373/-. Total amount to be spent for the financial year is Rs.14,74,373. The amount unspent, if any, is NIL.
Access essential information and documents to make informed investment decisions
Stay updated with upcoming events, conferences, and announcements
Access quarterly and half-yearly financial statements and reports
Download comprehensive annual reports and financial summaries
Access investor presentations, corporate briefings, and slideshows
Our blog provides insightful information about unlisted shares, offering a deeper understanding of how these assets work, their potential benefits, and the risks involved. Whether you're new to unlisted shares or looking to expand your knowledge, we cover topics such as investment strategies, valuation methods, market trends, and regulatory aspects. Stay updated with expert tips and guides to navigate the unlisted share market effectively.
Unlisted shares are stocks of companies that are not listed on any stock exchange, meaning they are not publicly traded. These shares are typically available for trade in the private market through brokers, and can offer unique investment opportunities.
You can buy unlisted shares through a broker or platform that specializes in unlisted share transactions. We provide a secure and easy way to purchase unlisted shares from top companies, ensuring a smooth transaction process.
The share prices of unlisted companies can fluctuate based on various factors like market demand, company performance, and private transactions. You can check the latest share prices for unlisted companies on our website for real-time updates.
Unlisted shares can offer higher growth potential, as they are typically not subject to the same market volatility as listed shares. However, they come with higher risk due to limited liquidity and availability of information. It's important to research thoroughly and consult experts before investing.
To sell unlisted shares, you can connect with a broker or platform that facilitates the sale of private stocks. We help investors buy and sell unlisted shares with ease, ensuring that your transaction is handled professionally and securely.
Yes, unlisted shares can eventually be listed on a stock exchange through an Initial Public Offering (IPO). This process allows the company to offer its shares publicly and be traded on major exchanges, potentially increasing liquidity and visibility.
Gains from unlisted shares are subject to capital gains tax in India. Short-term capital gains (if held for less than 24 months) are taxed at your applicable income tax rate, while long-term capital gains (if held for more than 24 months) are taxed at 20% with indexation benefits. Always consult a tax advisor for precise tax implications.
The value of unlisted shares is typically determined by private transactions, financial reports, and market demand. We provide the latest updates on share prices of unlisted companies, giving you the most accurate valuation available.
The minimum investment for unlisted shares can vary depending on the company and broker. Generally, the minimum investment is higher than for listed stocks, but we provide detailed information to help you make the best investment decisions.
Yes, unlisted shares may pay dividends if the company has declared them. However, since these companies may be in their growth stage, dividend payments are not always guaranteed. It's important to check the company's financial health before investing.
It's important to conduct thorough research on the company's financials, management, market potential, and overall business model. You can also seek professional advice from experts to help you choose unlisted shares with strong growth prospects.
Gains from unlisted shares are subject to capital gains tax in India. Short-term capital gains (if held for less than 24 months) are taxed at your applicable income tax rate, while long-term capital gains (if held for more than 24 months) are taxed at 20% with indexation benefits. Always consult a tax advisor for precise tax implications.
